[1]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55-58.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(01):55-58.
点击复制

白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年01
页码:
55-58
栏目:
临床研究
出版日期:
2023-02-13

文章信息/Info

Title:
The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma
作者:
蒋健强; 　李晓娟; 　李拥军; 　张卫华; 　于洪波; 　陈　橼
Author(s):
JIANG Jianqiang;  LI Xiaojuan;  LI Yongjun;  ZHANG Weihua;  YU Hongbo;  CHEN Yuan.
Department of Interventional Therapy, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province 226400, China
关键词:
【关键词】肝细胞癌; 白蛋白-胆红素评分; 肝功能衰竭; 肝动脉化疗栓塞
文献标志码:
A
摘要:
【摘要】　目的　对比白蛋白-胆红素评分与Child-Pugh评分预测巨块型肝细胞癌患者TACE术后发生肝功能衰竭的能力。方法　收集2017年1月至2021年9月南通大学附属肿瘤医院首次行TACE治疗的巨块型肝癌患者的临床资料。计算患者术前白蛋白-胆红素评分与Child-Pugh评分,分析不同的术前白蛋白-胆红素评分与Child-Pugh评分患者TACE术后肝功能衰竭的发生率。采用受试者工作特征曲线下面积（AUC）评价白蛋白-胆红素评分与 Child-Pugh评分对TACE术后肝功能衰竭发生的预测能力。结果　共纳入111例患者，36例（32.4%）发生TACE术后肝功能衰竭。白蛋白-胆红素评分为1级、2级和3级患者TACE术后肝功能衰竭的发生率分别为20.4%（11/54）、41.8%（23/55）和2/2，差异有统计学意义（P=0.013）。Child-Pugh评分为A级与B级患者TACE术后肝功能衰竭的发生率分别为28.9%（28/97）和8/14，差异有统计学意义（P=0.035）。Child-Pugh评分为A级但白蛋白-胆红素评分为1级和2级的患者肝功能衰竭发生率分别为20.4%（11/54）和39.5%（17/43），Child-Pugh评分为A级但白蛋白-胆红素评分为2级患者的TACE术后肝功能衰竭的发生率高于Child-Pugh评分为A级但白蛋白-胆红素评分为1级的患者，差异有统计学意义（P=0.039）。白蛋白-胆红素评分预测肝功能衰竭的AUC为0.80（95%CI:0.721～0.876），Child-Pugh评分的AUC为0.698（95%CI:0.604～0.782），差异有统计学意义（P=0.001）。结论　白蛋白-胆红素评分对TACE术后肝功能衰竭发生的预测能力优于Child-Pugh评分。

参考文献/References:

［1］　陈　荔，滕皋军. TACE对原发性肝癌肝功能的损伤［J］. 东南大学学报（医学版），2012，31:643-647.

［2］　赵淑芬，刘卓环，黄江远，等. 中晚期肝癌患者肝动脉化疗栓塞术后肝功能代偿不全影响因素分析［J］. 内科急危重症杂志，2019，25:19-20.

［3］　周　雄，邓　开，陈　俊，等. 影响TACE治疗原发性肝癌后肝功能损伤的相关因素研究［J］. 实用癌症杂志，2016，31:991-993.

［4］　Miksad RA, Ogasawara S, Xia F, et al. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study［J］. BMC Cancer, 2019, 19:795.

［5］　Park KH, Kim JH, Choe WH, et al . Risk factors for liver function deterioration after transarterial chemoembolization refractoriness in Child-Pugh class a hepatocellular carcinoma patients［J］. Korean J Gastroenterol, 2020, 75:147-156.

［6］　俞　婷，俞　谦，欧希龙，等. 原发性肝癌肝动脉化疗栓塞后严重肝功能失代偿的相关因素分析［J］. 现代医学，2009，37:20-23.

［7］　中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗临床实践指南［J］. 中华放射学杂志，2019，53：246-255.

［8］　Chan AWH, Leung HHW, Chong CCN, et al. Validating the ALBI grade: its current and future use in HCC prognostication［J］. J Hepatol, 2017, 66:661-663.

［9］　Rahbari NN, Gardon OJ, Padbuy R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery（ISGLS）［J］. Surgery, 2011, 149：713-724.

［10］张长坤，张龙辉，王　东，等. 术前肝功能Child-Pugh评分与白蛋白-胆红素评分对肝癌患者肝切除术后肝衰竭和预后的预测价值［J］. 中华消化外科杂志，2018，17:474-482.

［11］曾勇超，戴朝六，卜献民，等. ALBI评分与Child-Pugh评分对肝癌肝切除术后肝衰竭预测的比较［J］. 中华普通外科杂志，2019，34:649-651.

［12］谢浩荣，王　恺，周　杰. 白蛋白-胆红素评分与Child-Pugh评分预测肝癌患者术后肝功能衰竭的效果比较［J］. 中华肝胆外科杂志，2018，24:173-178.

［13］Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma［J］. J Gastroenterol Hepatol, 2016, 31:1031-1036.

［14］孙　玉，张洪海，生守鹏，等. 白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义［J］. 介入放射学杂志，2021，30:502-507.

［15］ Robald J, Wang Q, Choi SS, et al. Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt （TIPS）creation［J］. Diagn Interv Imaging, 2018, 99:163-168.

［16］ Kudo M. Recent advances in systemic therapy for hepatocellular carcinoma in an aging society: 2020 update［J］. Liver Cancer, 2020, 9:640-662.

 

相似文献/References:

[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(01):543.
[2]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(01):36.
[3]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(01):90.
[4]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):921.
[5]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):968.
[6]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(01):995.
[7]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(01):1039.
[8]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(01):1212.
[9]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(01):1269.
[10]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(01):1373.

备注/Memo

备注/Memo:
（收稿日期：2021-12-11）

（本文编辑：新　宇）　
更新日期/Last Update: 2023-02-13